ReviewVirus research2017
Developments in L2-based human papillomavirus (HPV) vaccines.
Review in Virus research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 75 citations in OpenAlex.
- Experimental Analysis of HPV16 L1/L2 Chimeric VLP Internalization by Human Peripheral Blood Leukocytes.International journal of molecular sciences · 2026Article
- Design and computational evaluation of a prophylactic and therapeutic multi-epitope vaccine candidate against cervical cancer.Virology journal · 2026Article
- A novel approach to HPV16 VLP construction and production with improved accessibility and particle sorting potential.Frontiers in molecular medicine · 2026Article
- Systems Vaccinology-Integrated Proteomics to Develop a Novel Prophylactic and Therapeutic Vaccine Against Human Papillomavirus 16.Bioinformatics and biology insights · 2026Article
- Impact of High-Risk HPV Infection on PI3K, MALAT1, H19 and LINC00460 Expression in Cervical Cells.Journal of cellular and molecular medicine · 2025Article
- Novel Strategies for Developing Next-Generation Vaccines to Combat Infectious Viral Diseases.Vaccines · 2025Review
- Genetic variations of theNarra J · 2025Article
- Case-Control Study of Cervicovaginal β/γ-Human Papillomavirus Infection in Women With Human Immunodeficiency Virus and Its Relation to Incident Cervical Precancer.The Journal of infectious diseases · 2025Article
- Prophylactic vaccines against HPV-caused cervical cancer: novel vaccines are still demanded.Infectious agents and cancer · 2025Review
- MS2 virus-like particles as a versatile platform for multi-disease vaccines: a review.Frontiers in immunology · 2025Review
- Review
- Immunoinformatics approach for design novel multi-epitope prophylactic and therapeutic vaccine based on capsid proteins L1 and L2 and oncoproteins E6 and E7 of human papillomavirus 16 and human papillomavirus 18 against cervical cancer.Osong public health and research perspectives · 2024Article
- Article
- Inter-epitope spacer variation within polytopic L2-based human papillomavirus antigens affects immunogenicity.NPJ vaccines · 2024Article
- Prevention and Treatment of HPV-Induced Skin Tumors.Cancers · 2023Review
- Pseudotyped Virus for Papillomavirus.Advances in experimental medicine and biology · 2023Article
- Searching for the methylation sites involved in human papillomavirus type 16 and 18‑positive women with cervical cancer.Molecular and clinical oncology · 2022Article
- Novel Vaccine Strategies and Factors to Consider in Addressing Health Disparities of HPV Infection and Cervical Cancer Development among Native American Women.Medical sciences (Basel, Switzerland) · 2022Review
- Human Papillomavirus Type 16 L2 Gene Sequence Variation Analysis in Indonesian Cervical Cancer Specimens.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Radiotherapy for HPV-related cancers: prediction of therapeutic effects based on the mechanism of tumor immunity and the application of immunoradiotherapy.Japanese journal of radiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Infections with sexually transmitted high-risk Human Papillomavirus (hrHPV), of which there are at least 15 genotypes, are responsible for a tremendous disease burden by causing cervical, and subsets of other ano-genital and oro-pharyngeal carcinomas, together representing 5% of all cancer cases worldwide. HPV subunit vaccines consisting of virus-like particles (VLP) self-assembled from major capsid protein L1 plus adjuvant have been licensed. Prophylactic vaccinations with the 2-valent (HPV16/18), 4-valent (HPV6/11/16/18), or 9-valent (HPV6/11/16/18/31/33/45/52/58) vaccine induce high-titer neutralizing antibodies restricted to the vaccine types that cause up to 90% of cervical carcinomas, a subset of other ano-genital and oro-pharyngeal cancers and 90% of benign ano-genital warts (condylomata). The complexity of manufacturing multivalent L1-VLP vaccines limits the number of included VLP types and thus the vaccines' spectrum of protection, leaving a panel of oncogenic mucosal HPV unaddressed. In addition, current vaccines do not protect against cutaneous HPV types causing benign skin warts, or against beta-papillomavirus (betaPV) types implicated in the development of non-melanoma skin cancer (NMSC) in immunosuppressed patients. In contrast with L1-VLP, the minor capsid protein L2 contains type-common epitopes that induce low-titer yet broadly cross-neutralizing antibodies to heterologous PV types and provide cross-protection in animal challenge models. Efforts to increase the low immunogenicity of L2 (poly)-peptides and thereby to develop broader-spectrum HPV vaccines are the focus of this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.